Investment
Features
FeesSafety
Academy
More
Pluang+

MMR vaccine split faces years-long FDA hurdles; IBM partners with OpenAI for AI boost; Jack in the Box shows early recovery signs.

Market News
13 Aug 2026
Seeking Alpha
View Source
Neutral
pluang ai news

President Trump's executive order to separate the combined MMR vaccine into individual shots faces significant regulatory and manufacturing challenges, with FDA approval potentially taking up to 10 years. Merck and GSK, the only licensed producers of the combined MMR vaccine, have not manufactured individual vaccines for decades and cite lack of scientific support for the split. Meanwhile, IBM is enhancing its AI capabilities by integrating OpenAI models like GPT-5.6 into its consulting platform, aiming to advance enterprise AI and cybersecurity solutions. Jack in the Box is showing early signs of operational improvement under interim leadership but continues to face challenges in a tough quick-service restaurant market. Additionally, investor Michael Burry is increasing short positions on several tech stocks, citing overvaluations after recent rallies.

More News (MRK)

Merck officer sells $1.46M in stock amid strong Q2 growth and lowered 2026 EPS guidance.

Merck officer sells $1.46M in stock amid strong Q2 growth and lowered 2026 EPS guidance.

Merck & Co. saw a significant stock sale by its Animal Health President, Richard R. DeLuca, who sold 11,099 shares worth about $1.46 million. The company reported strong Q2 results with revenues up 5% to $16.61 billion, driven by its cancer drug Keyt...

Market News
Neutral
1 day ago
Merck reports 5% revenue growth in Q2 2026, boosted by KEYTRUDA and pipeline drugs, with positive analyst outlook.

Merck reports 5% revenue growth in Q2 2026, boosted by KEYTRUDA and pipeline drugs, with positive analyst outlook.

Merck & Co. reported a 5% revenue increase to $16.6 billion in Q2 2026, driven by strong sales of its cancer drug KEYTRUDA at $8.4 billion and significant growth in pipeline products WELIREG and WINREVAIR. Analysts, including Daiwa, upgraded Merck to...

Company Fundamentals
Bullish
2 days ago
Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.

Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.

Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...

Market News
Bullish
2 days ago
Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.

Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.

Bio-Techne Corporation reported flat revenue of $1.2 billion for fiscal year 2026, with a 3% organic revenue increase in Q4. GAAP EPS rose to $1.16 for the full year from $0.46 last year, while adjusted EPS slightly increased to $1.93. The company hi...

Company Fundamentals
Bullish
2 days ago
Trump orders splitting MMR vaccine into three shots despite no scientific support and expert criticism.

Trump orders splitting MMR vaccine into three shots despite no scientific support and expert criticism.

President Donald Trump signed an executive order to separate the combined MMR vaccine into three individual shots, citing unproven claims linking the combined vaccine to autism. Medical experts strongly reject this, emphasizing the vaccine's safety a...

Market News
Bearish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App